Veeva Study Startup

Accelerate Study Start-up, Enroll Patients Faster

Study Startup manages the start-up activities of a trial, including feasibility, qualification, and activation of research sites.

Feasibility surveys are sent to research sites during the site selection phase. Sites are automatically scored based on their response, and those selected are routed into the site activation process.

Study Startup drives site activation through standard tasks and milestones. These are controlled through provided and flexible country intelligence templates that specify the processes and documentation required before activating a site.

Information is collected, tracked, and presented in dashboard views to deliver visibility of start-up progress and timelines.

Announced 2015 Status Mature Customers 11-50
Veeva Study Startup
Learn how AstraZeneca saves 260 working days for monitors
Read More
Overview

Accelerate Study Start-up, Enroll Patients Faster

Study Startup manages the start-up activities of a trial, including feasibility, qualification, and activation of research sites.

Feasibility surveys are sent to research sites during the site selection phase. Sites are automatically scored based on their response, and those selected are routed into the site activation process.

Study Startup drives site activation through standard tasks and milestones. These are controlled through provided and flexible country intelligence templates that specify the processes and documentation required before activating a site.

Information is collected, tracked, and presented in dashboard views to deliver visibility of start-up progress and timelines.

Impact

Improve operational efficiency

50%

decrease in average days from site selected to ready for enrollment

45%

faster to enroll the first subject after site initiation

42%

decrease from protocol approved to first subject enrolled

Why Veeva Study Startup

Manage end-to-end processes in one system

Customer Success

Finding and activating the right sites faster

Alexion Bayer BioNTech Boehringer-Ingelheim Ferring Fortrea GSK Novartis Novo-Nordisk Parexel Vertex